Use of a Computer-Assisted Decision Support (CADS) System in Management of Patients With Type 2 Diabetes



Status:Completed
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Start Date:July 2011
End Date:October 2012
Contact:Robert A. Vigersky, MD
Email:robert.vigersky@amedd.army.mil
Phone:202.782.6750

Use our guide to learn which trials are right for you!

The Use of a Computer-Assisted Decision Support (CADS) System to Improve Outcomes in Patients With Type 2 Diabetes

The primary purpose of this study is to determine whether the use of a computer assisted
decision support (CADS)system by primary care providers (PCPs) for their patients with type
2 diabetes mellitus (T2DM) changes the quality of care relative to a "usual care" group in
terms of objective outcome measures of glycemic control (e.g., A1C, mean blood glucose,
frequency of hypoglycemic episodes) and in terms of subjective ratings by patients.

Diabetes accounts for an enormous fraction of the cost of health care in the United States
and presents a major burden on Military Medical Facilities for care of retirees and
dependents. There are insufficient endocrinologists and other diabetes specialists to manage
all patients with diabetes mellitus (DM) and a significant fraction of these patients have
less than optimal control (hemoglobin A1C's [A1Cs] over 7%). Multiple barriers prevent the
necessary improvement in glycemic control that would result in savings in lives and costs.
The implementation of a telemedicine and web-based approach for patients to send their blood
glucose data which, when combined with relevant laboratory, pharmacy, and A1C targets as set
individually for each patient by the Primary Care Physician (PCP), triggers a clinical
decision support system (DSS) for the providers can be expected to improve quality of care
and efficiency of care. The computer assisted decision support (CADS) system has been
integrated with the Comprehensive Diabetes Management Program (CDMP), a web-based,
multi-platform, interactive patient and provider tool which is currently operative in the
Walter Reed Health Care System (WRHCS), Wilford Hall Medical Center (WHMC) at Lackland Air
Force Base (AFB), and five community clinics affiliated with the University of Hawaii (UH).
This existing infrastructure permits CADS to be tested in a multiple sites that are
geographically diverse with diverse patient populations.

This study will test the safety and efficacy of CADS as used by PCPs in a multi-site,
ethnically and geographically diverse study in a 12-month, open, prospective,
cluster-randomized, controlled clinical trial. The specific aims of the study are to: (1)
monitor the impact of the intervention on: a) measures of glycemic control, b) the number of
diabetes -related hospitalizations and emergency room visits, c) the control of
co-morbidities, hyperlipidemia and hypertension, d) the number of clinic visits, e) the
change in the patients' quality of life as a result of the intervention; and (2) evaluate
the PCPs' satisfaction with the technology.

We will employ a cluster-randomized, controlled, clinical trial involving 30 PCPs who will
each recruit approximately 19 patients from their respective geographic site. After
completion of recruitment, PCPs and their patients will be randomly assigned to 1 of 2
"treatment" categories: CADS, or "Usual Care". Input data for use by the CADS system will
come from the electronic medical record (laboratory and pharmacy data) and from the PCP who
will set goals for each individual patient's glycemic control. Patients will upload blood
glucose data through a modem to a password-protected, secure server at least every 2 weeks
and receive modification in their treatment regimen at least every three months from their
PCP, based in part on the recommendations provided by the CADS system to the PCP. We will
compare quantitative outcome measures of glycemic control (the primary outcome is the change
in the patient's A1C), blood pressure, and lipid levels from the two treatment groups. In
addition, subjective qualitative data from the patients and providers will be obtained.

Inclusion Criteria:

Providers

1. Non-specialist physician (general internist or family practitioner), nurse
practitioner, physicians assistant

2. Absence of orders for deployment or permanent change of station

3. Willingness to recruit up to 19 patients prior to randomization

4. Willingness to deliver "usual care" as defined below in Section 6.3.2.

Patients

- Patients with a diagnosis of Type 2 DM of at least three months duration;

- History of inadequate glycemic control (A1C < 7.0% but ≤ 11%) determined by at least
two A1C values within the previous 6 months

- Willingness to test blood glucose four or more times each day at least once a week,
and 8 times each day for one day per month;

- Willingness to upload their glucometer to transmit data to a central database every 2
weeks

- Access to a land line telephone in order to upload their glucometer data every 2
weeks

- Not using "prandial" regular or a short-acting insulin (e.g. insulin aspart, lispro,
glulisine)

- Not using "premixed insulin" (Novolin Mix, Novolog Mix, Humulin Mix, Humalog Mix)

- 18 years of age or older

- Stable medical status (e.g., no myocardial infarction, stroke, major surgery, or
major mental illness during the previous six months)

- Not taking or not expected to be taking any oral glucocorticoids except for
replacement therapy for those with adrenal insufficiency, amphetamines, anabolic, or
weight-reducing agents during the course of the study

- Not receiving chemotherapy or immunosuppressive therapy access to telephone capable
of transmitting data for downloading of a glucose meter

Exclusion Criteria:

Providers

1. Specialist physicians

2. Orders for deployment or permanent change of station

3. Unwillingness to recruit up to 19 patients prior to randomization

4. No prior experience with management of type 2 diabetes in adults

5. Unwillingness to deliver "usual care" as defined below

Patients

1. Patients with Type 1 diabetes or those with Type 2 on prandial rapid-acting insulin
or premixed insulins

2. Unwillingness to test blood glucose four or more times a day at least once a week and
8 times a day once a month;

3. Unwillingness or inability to receive training in using the technology and/or upload
blood glucose data every 2 weeks.

4. No access to a land line telephone in order to upload their glucometer data every 2
week

5. Inability to communicate in written and spoken English

6. Organ (kidney, pancreas, liver) transplant recipients

7. Severe impairment of dexterity, vision, or intellectual function

8. Pregnancy verified by a urine pregnancy test at baseline in pre-menopausal women. The
pregnancy test will be administered by the project officer at each study site.

9. Individuals who are not likely to return for the follow-up because they or their
sponsors are likely to have a permanent change of station or termination of service
before completion of the protocol
We found this trial at
1
site
6900 Georgia Ave NW
Washington, District of Columbia 20307
(202) 782-6849
Walter Reed Army Medical Center The Walter Reed National Military Medical Center is one of...
?
mi
from
Washington,
Click here to add this to my saved trials